What question did this study set out to answer?

To evaluate the use of immunohistochemistry for detecting replication error in colorectal cancer and its incidence among different patient subgroups.

September 1, 1999GutOpen Access

Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial assesses immunohistochemical tests for diagnosis in colorectal cancer, suggesting improved patient selection.

To evaluate the use of immunohistochemistry for detecting replication error in colorectal cancer and its incidence among different patient subgroups.
502 colorectal cancers were analyzed for RER positivity and hMSH2/hMLH1 expression.
Immunohistochemical analysis was performed to assess mismatch repair defects in patients.
Incidences of RER positivity were evaluated in distinct patient groups based on cancer type and age.
RER positivity was found in various subgroups: 50% for metachronous, 31% for synchronous, and 17% for those under age 50.
All RER positive tumors (100%) showed a lack of expression of hMSH2 or hMLH1.
Patients with mismatch repair defects had a significantly higher risk (5.54 times) of developing a metachronous colorectal cancer.

Cawkwell et al. (1999) studied this question.

View Full Paper

Ask AI

Bookmark